venetoclax
New Biomarker Predicts MDS Treatment Response
Researchers have identified a new biomarker to predict treatment response for myelodysplastic syndromes (MDS), ...
MARCH 22, 2022
Venclexta Approved for Treatment of Previously Untreated CLL/SLL
The FDA approved venetoclax (Venclexta, AbbVie/Genentech) for the treatment of adults with chronic lymphocytic ...
JUNE 5, 2019
FDA Halts MM Trial, Deaths Seen in Venclexta Arm
The FDA halted a clinical trial of Venclexta for MM because of an increased risk for death; does not affect ...
MARCH 22, 2019
Venclexta Approved for CLL/SLL After 1 Prior Therapy
The FDA granted regular approval to venetoclax in patients with chronic lymphocytic leukemia (CLL) or small ...
JUNE 18, 2018
FDA Approves Venclexta for Certain CLL in Patients
Venclexta is the first BCL-2 inhibitor in relapsed/refractory CLL patients with 17p deletion.
APRIL 12, 2016
